The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. (Q34393068)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24354461%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

title

The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24354461%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24354461%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Richard G B Langley

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24354461%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Judit Nyirady

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24354461%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Peter van de Kerkhof

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24354461%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Charis Papavassilis

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24354461%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

publication date

20 December 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24354461%20AND%20SRC:MED&resulttype=core&format=json

Journal of Dermatological Treatment

3 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24354461%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24354461%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24354461%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

23-31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24354461%20AND%20SRC:MED&resulttype=core&format=json

Psoriasis assessment tools in clinical trials

3 March 2020

cites work

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.865009

What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.865009

Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.865009

Randomized Clinical Trials for Psoriasis 1977–2000: The EDEN Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.865009

How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.865009

Cyclandelate in the Treatment of Senile Mental Changes: A Double-Blind Evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.865009

Outcome measures for psoriasis severity: a report from the GRAPPA 2012 annual meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.865009

Psoriasis outcome measures: a report from the GRAPPA 2012 annual meeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.865009

A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global Assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.865009

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.865009

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.865009

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.865009

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.865009

Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.865009

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.865009

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.865009

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.865009

Definition of treatment goals for moderate to severe psoriasis: a European consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.865009

Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.865009

Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.865009

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.865009

European S3-Guidelines on the systemic treatment of psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.865009

British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.865009

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.865009

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.865009

10.3109/09546634.2013.865009

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24354461%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference